|
Focus on Protein Kinases for Drug Development
ProQinase GmbH is a contract research organization (CRO) which provides a Protein Kinase Technology Platform for preclinical drug development of protein kinase inhibitors in oncology and other therapeutic areas. Currently 185 in-house produced recombinant protein kinases are offered for sale and 320 kinases are available for in vitro kinase assay services (HTS, selectivity profiling and IC50 determination). Hits derived from in vitro kinase assays can be characterized at ProQinase in cellular phosphorylation assays and in a cellular angiogenesis assay.
For further evaluation of lead compounds ProQinase offers various in vivo assays including subcutaneous xenograft and orthotopic tumor models, and an unique angiogenesis assay. ProQinase´s drug development service portfolio is completed by a clinical biomarker assay service for determination of different biomarker proteins in serum or plasma samples derived from clinical trials.
|